Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127,672,444
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
91,648,969
-
Shares change
-
+866,146
-
Total reported value, excl. options
-
$4,144,516,571
-
Value change
-
+$31,626,482
-
Put/Call ratio
-
31%
-
Number of buys
-
126
-
Number of sells
-
-82
-
Price
-
$45.22
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2022
258 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q2 2022.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91,648,969 shares
of 127,672,444 outstanding shares and own 72% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (11,542,743 shares), Avoro Capital Advisors LLC (9,805,000 shares), VANGUARD GROUP INC (8,726,745 shares), PRICE T ROWE ASSOCIATES INC /MD/ (8,679,813 shares), BlackRock Inc. (6,798,544 shares), EcoR1 Capital, LLC (5,183,431 shares), STATE STREET CORP (3,496,925 shares), Octagon Capital Advisors LP (2,583,059 shares), JENNISON ASSOCIATES LLC (2,298,347 shares), and GEODE CAPITAL MANAGEMENT, LLC (1,610,162 shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.